Hengrui Medicine makes first buyback of 335,000 shares, cumulative repurchase amount exceeds 2.8 billion yuan

Corporate ActionAnalyst

โดย 数据宝·

Summary · why it matters

Hengrui Medicine announced on the evening of September 17 its first buyback of A-shares, repurchasing 335,000 shares through centralized bidding that day, accounting for 0.005% of total share capital, with a total payment of 14.5036 million yuan. According to a previous announcement, the total repurchase funds this time are no less than 1 billion yuan and no more than 2 billion yuan, to be used for employee stock ownership plans or equity incentives, with an implementation period from August 19, 2026 to August 18, 2027. Since 2023, the company has issued four buyback plans, with cumulative repurchases reaching 2.855 billion yuan. According to statistics from Securities Times Data Treasure, as of September 17, 48 institutions have issued 1,990 buy-type ratings since September, covering 1,078 stocks, of which 64 stocks received ratings from five or more institutions. Sany Heavy Industry, Sailun Tire, and Anker Innovations each received ratings from 11 institutions, while BYD and Mindray Medical each received ratings from 10 institutions. Sany Heavy Industry's net profit attributable to the parent in the first half of the year was 5.69 billion yuan, up 9.13% year-on-year, and as of September 16, 2026, it had cumulatively repurchased 18.3685 million shares, paying 333 million yuan. Sailun Tire's net profit attributable to the parent in the first half was 2.16 billion yuan, up 17.97% year-on-year, with tire sales of 45.0135 million units in the first half, up 14.99% year-on-year. Among the 64 stocks, 28 received net margin buying since September, with Inspur Information, Inovance Technology, and China Yangtze Power ranking top in net buying amounts at 572 million yuan, 403 million yuan, and 280 million yuan respectively.